Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France

Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Dessenheim, Alsace, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Asthmatic patients treated for this disease with Symbicort Turbuhaler
Patients monitored for asthma by the doctor for at least 12 months
Patients seen in outpatient care at the baseline visit
Patients agreeing to participate in the study

Exclusion criteria

Patients with any chronic lower respiratory disease other than asthma
Patients receiving anti-IgE agents in the last 4 months
Patients receiving desensitisation treatment outside of the maintenance phase
Patients deemed to be unable to respond to the study for linguistic or cognitive reasons

Treatment and study plan

Primary outcomes

Level of control of the asthma

Time frame: 3 months
Evaluation of compliance with treatment

Time frame: 3 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma

Acronym: SYMBIOSE

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Dec 22, 2008
Registry last updated: Dec 29, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed